Immunotherapy, a revolutionary approach to cancer treatment, has garnered significant attention in the medical community. This technique leverages the body's immune system to combat cancerous cells, offering a promising alternative to traditional treatments. This article aims to elucidate the essential aspects of immunotherapy for physicians.
Immunotherapy, also known as biotherapy, involves stimulating or restoring the immune system's ability to fight infections and diseases. It can be classified into two types: active and passive. Active immunotherapy boosts the immune system to attack cancer cells, while passive immunotherapy involves the use of immune system components, such as monoclonal antibodies, to target cancer cells.
Immunotherapy encompasses various modalities, including monoclonal antibodies, immune checkpoint inhibitors, cancer vaccines, and adoptive cell therapy. Monoclonal antibodies are designed to bind to specific targets on cancer cells. Immune checkpoint inhibitors help the immune system recognize and attack cancer cells. Cancer vaccines, like the Sipuleucel-T for prostate cancer, stimulate the immune system to attack specific types of cancer cells. Adoptive cell therapy involves enhancing the natural cancer-fighting ability of the patient's T cells.
Immunotherapy offers several benefits, including precision targeting of cancer cells, reduced side effects, and potential for long-term cancer control. However, it also carries risks, such as immune-related adverse events (irAEs) like inflammation and autoimmune reactions. Physicians should carefully consider these factors when deciding on a treatment plan.
Immunotherapy represents a significant stride in cancer treatment, offering a novel approach that leverages the body's own defenses. As research progresses, it is hoped that this treatment modality will become increasingly effective and widely accessible. Physicians must stay abreast of these developments to provide the best care for their patients.
1.
Rural colon cancer patients face higher risks, but minimally invasive surgery could narrow gap
2.
Chemotherapy before surgery helps patients with nose and sinus cancer avoid debilitating eye and bone removal
3.
Laryngeal Transplant Helped a Cancer Patient Speak Again in Pioneering Study
4.
The amount of liver tissue removed during gallbladder surgery has no discernible impact on overall survival.
5.
Long-Acting Interferon Therapy Approved for ET
1.
Molecular Network Mapping in Hematologic Disease
2.
Metabolic Reprogramming of the Tumor Microenvironment: Mechanisms, Clinical Relevance, and Emerging Therapeutic Strategies
3.
Hematopoietic Stem Cell Clonal Dynamics Across the Lifespan
4.
Connected Hematology Laboratory Networks for Automated Cross-Institution Data Exchange
5.
Digital Oncology Ecosystems Integrating Longitudinal Patient Trajectories: Transforming Cancer Care through Data-Driven Innovation
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
2.
Common side effects of cancer treatment and how they are managed
3.
Clinical Excellence in Hematology
4.
Best Practices in Hematology
5.
Current Scenario of Blood Cancer- Further Discussion on Genomic Testing & Advancement in Diagnosis and Treatment
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation